TrialX, a leader in building enterprise clinical trial patient recruitment and remote clinical research data collection platforms has collaborated with the ALK Positive - a patient-driven organization dedicated to improving the lives of ALK Positive patients worldwide. TrialX’s global clinical trial finder was selected to power ALK Positive’s Trial Finder - an up-to-date tool to help the ALK+ lung cancer patient community easily find information on relevant clinical trials focusing on ALK+ lung cancer and connect with study teams.

“We’re proud to partner with ALK Positive to empower patients with access to the latest clinical trial opportunities,” said Sharib Khan, Co-founder and CEO, TrialX. “Our goal is to simplify the search for clinical trial options and ensure that every individual affected by ALK+ lung cancer can make informed, confident decisions about their care through technology that is capable of understanding their needs.”

While registries such as ClinicalTrials.gov provide extensive listings of clinical trials across the U.S. and around the world, navigating them can often be overwhelming. The information is typically presented in a technical format, making it challenging for many individuals—especially those considering clinical trials as a treatment option—to locate and understand studies that may be relevant to them. To simplify this process for people affected by ALK+ lung cancer, ALK Positive’s Clinical Trial Finder leverages TrialX’s AI-driven technology to create an intuitive and accessible search experience. The platform guides patients and caregivers through a series of personalized questions to identify trial matches tailored to their specific health history and geographic location. For those who prefer to explore independently, the tool also includes advanced filters that allow searches by keyword, trial type, phase, and location. Both guided and self-search options offer clear, easy-to-understand trial summaries, prescreeners to help assess eligibility, and seamless ways to connect directly with study teams. Additionally, users can register to receive alerts about upcoming research opportunities, enabling them to stay informed and actively engaged in the clinical research landscape.

“Clinical trials are vital for driving progress and offering new hope to people living with ALK-positive lung cancer,” said Dr. Ken Culver, Executive Director and Medical Director at  ALK Positive. “Through our collaboration with TrialX, we’re empowering patients and families with a trusted resource to find and understand trials that may be right for them — helping transform what can often feel like an overwhelming search into an informed and hopeful journey.” ALK+ lung cancer occurs when an ALK gene fuses with another gene that drives uncontrolled cell growth. While scientists aren’t sure why some people develop ALK+ lung cancer, joining a clinical trial can offer access to potential new treatments — and renewed hope. "As this is a global ALK+ lung cancer trial database, the clinical trial finder accommodates multiple language options." added Dr. Culver.